Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall E Millikan

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Biometrics|November 7, 2003
Dose-finding with two agents in Phase I oncology trialsPeter F Thall, Randall E Millikan, Peter Mueller, et al.
Journal of the American Statistical Association|September 8, 2012
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate CancerLu Wang, Andrea Rotnitzky, Xihong Lin, et al.
Statistics in Medicine|April 12, 2007
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall, Leiko H Wooten, Christopher J Logothetis, et al.
Cancer|June 5, 2003
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastasesLance C Pagliaro, Ebrahim S Delpassand, Dallas Williams, et al.
Urologic Oncology|April 10, 2003
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II studyJeri Kim, Randall E Millikan, Terry L Smith, et al.
Journal of the National Cancer Institute|November 1, 2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall, Christopher Logothetis, Lance C Pagliaro, et al.
The Journal of Urology|March 12, 2003
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experienceArlene O Siefker-Radtke, Jason Gee, Yu Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinomaLance C Pagliaro, Randall E Millikan, Shi-Ming Tu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancerRandall E Millikan, Sijin Wen, Lance C Pagliaro, et al.
The Journal of Urology|November 20, 2012
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosisFarshid Dayyani, Bogdan A Czerniak, Kanishka Sircar, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Biometrics|November 7, 2003
Dose-finding with two agents in Phase I oncology trialsPeter F Thall, Randall E Millikan, Peter Mueller, et al.
Journal of the American Statistical Association|September 8, 2012
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate CancerLu Wang, Andrea Rotnitzky, Xihong Lin, et al.
Statistics in Medicine|April 12, 2007
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall, Leiko H Wooten, Christopher J Logothetis, et al.
Cancer|June 5, 2003
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastasesLance C Pagliaro, Ebrahim S Delpassand, Dallas Williams, et al.
Urologic Oncology|April 10, 2003
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II studyJeri Kim, Randall E Millikan, Terry L Smith, et al.
Journal of the National Cancer Institute|November 1, 2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall, Christopher Logothetis, Lance C Pagliaro, et al.
The Journal of Urology|March 12, 2003
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experienceArlene O Siefker-Radtke, Jason Gee, Yu Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinomaLance C Pagliaro, Randall E Millikan, Shi-Ming Tu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancerRandall E Millikan, Sijin Wen, Lance C Pagliaro, et al.
The Journal of Urology|November 20, 2012
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosisFarshid Dayyani, Bogdan A Czerniak, Kanishka Sircar, et al.
Pageof 4